Celldex Therapeutics (CLDX) Operating Leases (2019 - 2026)
Celldex Therapeutics' (CLDX) quarterly Operating Leases came in at $443000.0 in Q1 2026, down 77.03% year-on-year from $1.9 million in Q1 2025, and down 43.49% quarter-over-quarter from $784000.0 in Q4 2025.
Celldex Therapeutics (CLDX) Operating Leases (2019 - 2026) Analysis & Trends
Celldex Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $443000.0 for Q1 2026.
- On a quarterly basis, Operating Leases fell 77.03% year-over-year to $443000.0 in Q1 2026; TTM through Mar 2026 was $443000.0, a 77.03% decrease from a year earlier, with the FY2025 full-year figure at $784000.0, down 66.79% from the prior year.
- Operating Leases eased to $443000.0 in Q1 2026 per CLDX's latest filing, from $784000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $2.6 million in Q4 2022 and bottomed at $443000.0 in Q1 2026.
- The 5-year median for Operating Leases is $1.5 million (2025), against an average of $1.5 million.
- Across the five-year window, Operating Leases plunged 78.21% in 2024 and soared 310.43% in 2025, its largest moves.
- Year by year, Operating Leases stood at $2.6 million in 2022, then slumped by 64.14% to $928000.0 in 2023, then soared by 154.42% to $2.4 million in 2024, then slumped by 66.79% to $784000.0 in 2025, then slumped by 43.49% to $443000.0 in 2026.
- Per Business Quant, the three latest CLDX Operating Leases figures stand at $443000.0 (Q1 2026), $784000.0 (Q4 2025), and $1.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 443,000.00 |
| Dec 31, 2025 | 784,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 2.36 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 796,000.00 |
| Mar 31, 2024 | 470,000.00 |
| Dec 31, 2023 | 928,000.00 |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.73 Mn |
| Mar 31, 2023 | 2.16 Mn |
| Dec 31, 2022 | 2.59 Mn |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 841,000.00 |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 1.45 Mn |